While MHC restriction can represent a limitation, the use of target peptides associated to commonly expressed HLAs, such as HLA-A2 or T1D risk associated class II haplotypes, potentially allows to treat a significant proportion of subjects with relatively few different TCRtg-Treg. Here, HLA-C is linked to type 1 diabetes mellitus.